NO20091423L - Pyrimidinderivater og deres anvendelse som kinaseinhibitorer - Google Patents

Pyrimidinderivater og deres anvendelse som kinaseinhibitorer

Info

Publication number
NO20091423L
NO20091423L NO20091423A NO20091423A NO20091423L NO 20091423 L NO20091423 L NO 20091423L NO 20091423 A NO20091423 A NO 20091423A NO 20091423 A NO20091423 A NO 20091423A NO 20091423 L NO20091423 L NO 20091423L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
pyrimidine derivatives
pyrimidine
derivatives
kinase
Prior art date
Application number
NO20091423A
Other languages
English (en)
Inventor
James W Darrow
Kevin S Currie
Peter A Blomgren
Seung H Lee
Original Assignee
Cgi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cgi Pharmaceuticals Inc filed Critical Cgi Pharmaceuticals Inc
Publication of NO20091423L publication Critical patent/NO20091423L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091423A 2006-09-11 2009-04-07 Pyrimidinderivater og deres anvendelse som kinaseinhibitorer NO20091423L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84383606P 2006-09-11 2006-09-11
PCT/US2007/078154 WO2008033834A1 (en) 2006-09-11 2007-09-11 Pyrimidines derivatives and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20091423L true NO20091423L (no) 2009-06-10

Family

ID=38884547

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091423A NO20091423L (no) 2006-09-11 2009-04-07 Pyrimidinderivater og deres anvendelse som kinaseinhibitorer

Country Status (18)

Country Link
US (1) US20080125417A1 (no)
EP (1) EP2069314A1 (no)
JP (1) JP2010502749A (no)
KR (1) KR20090061655A (no)
CN (1) CN101605766A (no)
AR (1) AR063946A1 (no)
AU (1) AU2007296550A1 (no)
BR (1) BRPI0716888A2 (no)
CA (1) CA2661938A1 (no)
CL (1) CL2007002641A1 (no)
IL (1) IL197231A0 (no)
MX (1) MX2009002648A (no)
NO (1) NO20091423L (no)
PE (1) PE20081059A1 (no)
RU (1) RU2009113691A (no)
TW (1) TW200829577A (no)
WO (1) WO2008033834A1 (no)
ZA (1) ZA200901593B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701275C (en) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
ES2554615T3 (es) * 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
EP2665711A1 (en) * 2011-01-21 2013-11-27 Abbvie Inc. Picolinamide inhibitors of kinases
CN103889962B (zh) * 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
HUE059230T2 (hu) * 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
CN103732596B (zh) 2011-07-08 2016-06-01 诺华股份有限公司 吡咯并嘧啶衍生物
CN103073508B (zh) 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
US9782406B2 (en) 2011-10-25 2017-10-10 Peking University Shenzhen Graduate School Kinase inhibitor and method for treatment of related diseases
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
PE20141686A1 (es) 2011-11-03 2014-11-08 Hoffmann La Roche Compuestos de piperazina alquilados como inhibidores de actividad btk
RU2622391C2 (ru) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
RU2014126750A (ru) * 2011-12-09 2016-01-27 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN104109127B (zh) * 2013-04-19 2019-11-05 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
ES2619125T3 (es) 2013-04-25 2017-06-23 Beigene, Ltd. Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
KR101815360B1 (ko) 2013-07-03 2018-01-04 에프. 호프만-라 로슈 아게 헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
CN105745202A (zh) * 2013-09-03 2016-07-06 卡尔那生物科学株式会社 新型2,6-二氨基嘧啶衍生物
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗pd−1抗体並びにその治療及び診断のための使用
SI3052476T1 (sl) 2013-09-30 2020-12-31 Guangzhou Innocare Pharma Tech Co., Ltd. Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CA2929918C (en) 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
MX370103B (es) * 2013-12-11 2019-12-02 Biogen Ma Inc Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗pd−l1抗体並びにその治療及び診断のための使用
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
ES2913494T3 (es) 2016-02-29 2022-06-02 Hoffmann La Roche Composiciones de forma farmacéutica que comprenden un inhibidor de tirosina cinasa de Bruton
AU2017240609B2 (en) 2016-03-31 2021-07-15 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
CN109563099B (zh) 2016-08-16 2023-02-03 百济神州有限公司 一种化合物的晶型、其制备和用途
AU2017313085A1 (en) 2016-08-19 2019-03-14 Beigene Switzerland Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
JP2019529419A (ja) 2016-09-19 2019-10-17 エムイーアイ ファーマ,インク. 併用療法
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
TW201836642A (zh) 2017-03-24 2018-10-16 美商建南德克公司 治療自體免疫及發炎疾病的方法
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
WO2023080732A1 (ko) * 2021-11-05 2023-05-11 주식회사 유빅스테라퓨틱스 Btk 단백질 분해 활성을 갖는 화합물 및 이들의 의약 용도
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014022D0 (en) * 2000-06-08 2000-08-02 Novartis Ag Organic compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE454378T1 (de) * 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AU2004278413B2 (en) * 2003-09-30 2008-07-31 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
AU2005309732A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation JNK inhibitors for treatment of CNS injury
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2007296550A1 (en) 2008-03-20
US20080125417A1 (en) 2008-05-29
CN101605766A (zh) 2009-12-16
JP2010502749A (ja) 2010-01-28
WO2008033834A1 (en) 2008-03-20
BRPI0716888A2 (pt) 2013-10-22
CA2661938A1 (en) 2008-03-20
RU2009113691A (ru) 2010-10-20
PE20081059A1 (es) 2008-10-22
KR20090061655A (ko) 2009-06-16
ZA200901593B (en) 2010-03-31
CL2007002641A1 (es) 2008-06-20
AR063946A1 (es) 2009-03-04
IL197231A0 (en) 2009-12-24
MX2009002648A (es) 2009-03-26
EP2069314A1 (en) 2009-06-17
TW200829577A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
NO20091423L (no) Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2261223T3 (da) Pyrimidinderivater anvendt som PI-3-kinasehæmmere
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK2132194T3 (da) Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
DK2049557T3 (da) 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
NO20084764L (no) Tioksantinderivater og deres anvendelse som MPO inhibitorer
DK1841757T3 (da) Heteroaromatiske quinolin-forbindelser og deres anvendelse som PDE10-hæmmere
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
NO20084533L (no) Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK2252597T3 (da) Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer
DK1979326T3 (da) Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
DK2848610T3 (da) Hæmmere af kinaseaktivitet
BRPI0716781A2 (pt) Inibidores da quinase
DK1943243T3 (da) Kinase-inhibitorer
DK1723135T3 (da) Kendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som pde4-inhibitorer
ATE433449T1 (de) Kinaseinhibitoren
ATE520664T1 (de) Tyrosinkinase-hemmer
DK2148876T3 (da) Pyrazolonderivater som PDE4-inhibitorer
NO20084739L (no) Substituerte 3-cyanopyridiner som protein kinase inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application